DiaSys Corporation Expands Patent Claims for Bence Jones Protein Immunoassay to Include Monitoring, Screening and Adjunctive Testing For Several Disease States.

Business Editors/Health/Medical Writers

WATERBURY, Conn.--(BUSINESS WIRE)--June 7, 2004

DiaSys Corporation (AMEX:DYX):

-- Included in the expanded patent claims are Diagnostic and

Early Detection of Cancer, Kidney Disease, Diabetes and

Hypertension. When These Diseases are Detected Early, Medical

Management and the Quality of Life are Improved.

-- The Test is Simple and Inexpensive.

DiaSys Corporation (AMEX:DYX) a global healthcare products company announced today that it has amended patent claims to its proprietary immunoassay to detect free light chains in urine. The test has been expanded to include monitoring, screening and adjunctive test claims for Multiple Myeloma, MGUS (Monoclonal Gammopathy of Undetermined Significance), Waldstrom's Macroglobulinemia, Amyloidosis and Fanconi's Syndrome.

Morris Silverman, Chairman of the Board of DiaSys Corporation stated, "Huge advances have been made in protein analysis techniques and monoclonal antibody development, which we believe will now enable the company to commercialize its' patented technology when testing is completed. When this test is used with regular annual physicals, the demand in the United States alone could exceed 100 million in the general population.

Current testing methods are technically difficult, slow and expensive. DiaSys' urine test is a unique, non-invasive dipstick format, measuring kappa and lambda light chains separately, with minimal operator time, reduced processing time, antibody-linked specificity, high sensitivity, with all reagents included.

DiaSys Europe is currently assessing the patient populations for these disease states in the European Union, including the new member countries admitted May 1, 2004. New member countries add 75 million people to the EU bringing the population of European Community members to 455 million people.

DiaSys Corporation intends, in the future, to develop the other disease states which were filed in its original patent. These included Micromolecular Myeloma, Chronic Lymphatic Leukemia, Lupus Erythematosus, and Acute Rheumatoid Arthritis.

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation.

This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for complete description of, and discussions about, the Company.